Freedom Bio is a clinical stage biotech platform with phase 2 programs and 4 pre-clinical programs addressing the biggest shortcoming of first generation psychedelics. The company’s programs are based on 30+ years of work at Dr. John Krystal’s lab at Yale University.
Total raised: $10.5M
Investors 7
Funding Rounds 1
| Date | Series | Amount | Investors |
| 23.08.2022 | Seed | $10.5M | - |
Mentions in press and media 3
| Date | Title | Description |
| 27.03.2023 | Here are the 15 hottest startups in the psychedelics industry, according to top investors | From left: Sherry Rais, a cofounder and the CEO of Enthea; Mark Rus, the CEO of Delix Therapeutics; Jackie von Salm, a cofounder and the CSO of Psilera; Jimmy Qian, a cofounder and the president of Osmind. Sherry Rais/Enthea; Mark Rus/Delix... |
| 15.02.2023 | LongeVC Invests in Freedom Biosciences | Freedom Biosciences, a US biotechnology platform developing next-generation psychedelic therapeutics, received an investment from LongeVC. The amount of the deal was not disclosed. The company intends to use the funds to expand operations a... |
| 23.08.2022 | Freedom Biosciences Raises $10.5M in Seed Financing | Freedom Biosciences, a San Francisco, CA-based provider of a clinical-stage biotechnology platform to advance ketamine and psychedelic therapeutics, raised $10.5M in Seed funding. The round was led by MBX Capital with participation from Psy... |